ArticlePharmacoEconomics2018

Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist.

Przemysław Holko et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.